Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcos E Milla

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Molecular Pharmacology|December 26, 2008
Facilitatory interplay in alpha 1a and beta 2 adrenoceptor function reveals a non-Gq signaling mode: implications for diversification of intracellular signal transductionAlicja J Copik, Cynthia Ma, Alan Kosaka, et al.
Biochemistry|July 24, 2002
The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivityMohita J Mohan, Theresa Seaton, Justin Mitchell, et al.
Plos One|January 22, 2015
Isoproterenol acts as a biased agonist of the alpha-1A-adrenoceptor that selectively activates the MAPK/ERK pathwayAlicja J Copik, Aleksander Baldys, Khanh Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2007
Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injuryLi Zhu, Wolfgang Bergmeier, Jie Wu, et al.
British Journal of Pharmacology|July 2, 2010
AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonistJoel R Gever, Rothschild Soto, Robert A Henningsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2024
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based ImmunotherapiesKirk D Beebe, Joel R Eisner, John Guo, et al.
Cancer Research Communications|March 16, 2023
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal CancerJoel R Eisner, Kirk D Beebe, Gregory M Mayhew, et al.
Journal of Biomolecular Screening|October 8, 2015
Polypharmacology of Small-Molecule Modulators of the 5-Lipoxygenase Activating Protein (FLAP) Observed via a High-throughput Lipidomics PlatformJiao Song, Xuejun Liu, Jian Zhu, et al.
Journal of Medicinal Chemistry|March 17, 2017
Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein-Protein InteractionJonathan M Blevitt, Michael D Hack, Krystal L Herman, et al.
Nature Communications|August 10, 2021
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organismJerod L Ptacin, Carolina E Caffaro, Lina Ma, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Molecular Pharmacology|December 26, 2008
Facilitatory interplay in alpha 1a and beta 2 adrenoceptor function reveals a non-Gq signaling mode: implications for diversification of intracellular signal transductionAlicja J Copik, Cynthia Ma, Alan Kosaka, et al.
Biochemistry|July 24, 2002
The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivityMohita J Mohan, Theresa Seaton, Justin Mitchell, et al.
Plos One|January 22, 2015
Isoproterenol acts as a biased agonist of the alpha-1A-adrenoceptor that selectively activates the MAPK/ERK pathwayAlicja J Copik, Aleksander Baldys, Khanh Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2007
Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injuryLi Zhu, Wolfgang Bergmeier, Jie Wu, et al.
British Journal of Pharmacology|July 2, 2010
AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonistJoel R Gever, Rothschild Soto, Robert A Henningsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2024
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based ImmunotherapiesKirk D Beebe, Joel R Eisner, John Guo, et al.
Cancer Research Communications|March 16, 2023
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal CancerJoel R Eisner, Kirk D Beebe, Gregory M Mayhew, et al.
Journal of Biomolecular Screening|October 8, 2015
Polypharmacology of Small-Molecule Modulators of the 5-Lipoxygenase Activating Protein (FLAP) Observed via a High-throughput Lipidomics PlatformJiao Song, Xuejun Liu, Jian Zhu, et al.
Journal of Medicinal Chemistry|March 17, 2017
Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein-Protein InteractionJonathan M Blevitt, Michael D Hack, Krystal L Herman, et al.
Nature Communications|August 10, 2021
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organismJerod L Ptacin, Carolina E Caffaro, Lina Ma, et al.
Pageof 4